Use of Pregabalin and Worsening Heart Failure: A Nationwide Cohort Study
- PDF / 1,049,557 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 10 Downloads / 161 Views
ORIGINAL RESEARCH ARTICLE
Use of Pregabalin and Worsening Heart Failure: A Nationwide Cohort Study Marie Lund1,2 · Gry Poulsen1 · Björn Pasternak1,3 · Niklas Worm Andersson1,2 · Mads Melbye1,4,5 · Henrik Svanström1,3
© Springer Nature Switzerland AG 2020
Abstract Introduction Concerns regarding the increased risk of worsening heart failure with pregabalin have been raised. We assessed the association between use of pregabalin and risk of worsening heart failure in routine clinical practice. Methods We conducted a population-based cohort study in Denmark using data from nationwide registers, from 1 January 2008 to 31 December 2017. The study population consisted of patients 50 years of age or older with a diagnosis of heart failure who were new users of pregabalin or gabapentin (active comparator). We matched a total of 1395 new users of pregabalin to 1395 new users of gabapentin on a propensity score based on 55 covariates. Using proportional hazards regression, we estimated hazard ratios (HRs) for worsening heart failure (hospitalization with, or death from, heart failure) within 90 days of the start of treatment. Results We observed 33 patients with worsening heart failure among users of pregabalin [incidence rate (IR) 105.7 per 1000 person-years] versus 43 patients among users of gabapentin (IR 133.8 per 1000 person-years), corresponding to an HR of 0.79 [95% confidence interval (CI) 0.50–1.23]. The corresponding absolute risk difference was − 28.6 (95% CI − 66.8 to 31.3) per 1000 person-years. In sensitivity analysis using duloxetine as an alternative active comparator, including 847 new users of pregabalin and 847 new users of duloxetine, the results were similar (HR 1.08, 95% CI 0.60–1.94). Conclusions The present study found no evidence to support an association between the use of pregabalin and increased risk of worsening heart failure, compared with gabapentin and duloxetine. Key Points Pregabalin is approved for the treatment of peripheral and central neuropathic pain, epilepsy, and generalized anxiety disorder. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40264-020-00969-6) contains supplementary material, which is available to authorized users. * Marie Lund [email protected] 1
Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
2
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospitals, Copenhagen NV, Denmark
3
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
4
Department of Clinical Medicine, University of Copenhagen, Copenhagen N, Denmark
5
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
In recent years, the use of pregabalin has increased across the world. Concerns have been raised that pregabalin might imply an increased risk of worsening heart failure. We assessed whether the use of pregabalin is associated with worsening heart failure and found no evidence to support
Data Loading...
